SEC Filing Summary: ChromaDex Corporation (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by ChromaDex Corporation (not Niagen Bioscience, Inc.) on June 6, 2016, reporting events occurring on June 3, 2016. The filing details the entry into a Material Definitive Agreement regarding a registered direct offering of common stock.
Key Financial Metrics and Transaction Details
- Offering Size: 1,117,022 shares of common stock.
- Purchase Price: $4.70 per share.
- Total Gross Proceeds: Approximately $5.25 million (calculated as 1,117,022 shares x $4.70).
- Debt Retirement: The Company intends to use $4,857,948.52 of net proceeds to fully retire outstanding indebtedness owed to Hercules Technology II, L.P. under a September 29, 2014 loan agreement.
- Remaining Proceeds: To be used for general corporate purposes.
- Underwriting: No underwriter or placement agent was engaged.
Material Changes
The primary material change is the reduction of the Company's debt load. Upon closing, the Company will eliminate its term loan obligation to Hercules Technology II, L.P., which had a maximum access amount of $5,000,000. The filing does not provide comparative revenue, profit, or cash flow metrics for the period.
Outlook, Risks, and Management Commentary
Management intends to close the offering on or about June 6, 2016, subject to customary closing conditions. The offering is made pursuant to an effective Registration Statement on Form S-3 filed in May 2015. The filing explicitly states that the Purchase Agreement contains representations and warranties solely for the benefit of the parties involved and should not be relied upon by the public for factual information about the Company's current state of affairs.
Investor Verification Checklist
- Verify the actual closing date of the offering (expected June 6, 2016).
- Confirm the exact amount of net proceeds after deducting transaction costs.
- Review the Company's subsequent filings to confirm the full retirement of the Hercules Technology II, L.P. debt.
- Check for any dilution impact on existing shareholders from the issuance of 1,117,022 new shares.
- Review the Form S-3 Registration Statement (File No. 333-203204) for broader context on the Company's financial health.